Harvard Onconephrology Symposium 2026 – Videos + Slides

Harvard Medical School Continuing Education | Onconephrology Symposium 2026

The Harvard Onconephrology Symposium 2026 is an advanced two-day educational program focused on the rapidly evolving intersection of nephrology, oncology, hematology, cancer therapeutics, and kidney disease.

Developed for clinicians managing patients with cancer and renal complications, the symposium brings together experts to discuss emerging evidence, diagnostic challenges, novel cancer therapies, kidney toxicities, glomerular disease, monoclonal disorders, transplantation, and practical approaches to complex onconephrology cases. Pasted text

📌 Course Details

Course: Harvard Onconephrology Symposium 2026
Dates: September 17–18, 2026
Duration: 2 Days
Specialties: Nephrology • Oncology & Hematology • Pharmacology
Format: Videos + Slides
Institution: Harvard Medical School Continuing Education
Offered by: Brigham and Women’s Hospital & Dana-Farber Cancer Institute
Year: 2026

🎯 What You’ll Learn

The Harvard Onconephrology Symposium 2026 provides an extensive review of renal complications associated with cancer and modern cancer therapy.

Key learning areas include:

• Diagnosis and management of renal complications in patients with cancer
• Cancer-associated glomerular diseases
• Thrombotic microangiopathy
• Monoclonal gammopathies
• Kidney transplantation in patients with cancer
• Chemotherapy-associated nephrotoxicity
• Cellular and immune cancer therapies
• Targeted cancer treatments
• Reno-protective strategies
• Multidisciplinary management of complex cancer patients

These areas reflect the stated learning objectives of the official symposium.

📚 Harvard Onconephrology Symposium 2026 – Full Program

Day 1 – Thursday, September 17, 2026

HSCT, Immunotherapy & Cancer-Associated Kidney Injury

Welcome From Course Directors
Shruti Gupta; Raad Chowdhury

Welcome Message from a Pioneer
Joseph Bonventre

What Do BMT Docs Wish Nephrologists Knew about HSCT?
Corey Cutler

Changing Diagnostic and Treatment Landscape of HSCT-TMA
Sumithra Vasu

Cancer and Complementology
Anuja Java

Murine Models and Immune Therapy: What Can Mice Teach us About AIN?
Sandra Herrmann

The morning program then moves into immune checkpoint inhibitor-associated renal disease, including Beyond Biopsy: Biomarkers and Treatments for ICI-AKI, non-renal immune-related adverse events, and a multidisciplinary discussion of ICI-GN.

CAR-T, Cancer Therapy & Kidney Function

Toxicities of CAR-T and CAR-Treg
Sarah Nikiforow

How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment
Allison Betof

MAGnificent Properties of Cisplatin: Mitigating Risk and Managing AKI
Edgar Jaimes

Target Trial Emulation in Onconephrology
David Leaf

What’s the GFR!? Current Challenges in Cancer and Future Opportunities
Aisha Shaikh

How Would I Dose Chemotherapy? A Case Review
Abhijat Kitchlu

Glomerular Disease & Cancer-Associated Nephrotoxicity

Podocytes: An Innocent Bystander in Cancer
Astrid Weins

Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors?
Api Chewcharat

SGLT2is: Are they a Miracle For Cancer-Associated Nephrotoxicity Too?
María José Soler

Immune Complex Disease in Cancer: Future of Antigens
Sujal Shah

Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge?
Biruh Workeneh; Astrid Weins; Harish Seethapathy; Aisha Shaikh

Palliative Care in Onconephrology: Symptom Management and Decision Support
Samantha Gelfand

Day 2 – Friday, September 18, 2026

Day 2 focuses heavily on amyloidosis, plasma-cell disorders, MGRS, immunoglobulin-mediated kidney injury, transplantation and light-chain disease.

Featured Sessions

The Other Renal Amyloids: It’s not ALL about AL Amyloid
Vaishali Sanchorawala

Pathophysiology of Cancer Therapy and Cardiotoxicity
Anju Nohria

MGUS to Myeloma: Bench to the Bedside
Nikhil Munshi

IKMG Update on MGRS: Future Associations and Mechanisms
Samih H. Nasr

How do Immunoglobulins Cause Kidney Damage?
Christophe Sirac

The Onconephrology Jeopardy Challenge
Shruti Gupta; Kenar Jhaveri

How I Manage IgM Disease and Systemic Impact
Jorge J. Castillo

Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific)
Nelson Leung

The Clone That Stole the Gift: Transplant MGRS Case Review
Christopher Blosser; Raad Chowdhury

Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist
Christopher Blosser

The War Against Light Chains: A Case Debate
Raad Chowdhury; Sujal Shah; Nelson Leung; Kenar Jhaveri

Final Reflections / Poster Winners

👨‍⚕️ Course Directors

Raad Chowdhury, MD, FASN

Course Director
Medical Director of Onconephrology, Brigham and Women’s/Dana-Farber Cancer Institute
APD, Mass General Brigham Nephrology Fellowship, Harvard Medical School

Shruti Gupta, MD, MPH

Course Director
Director of Onconephrology, Brigham and Women’s/Dana-Farber Cancer Institute
Assistant Professor, Harvard Medical School

👥 Who Should Study This Course?

This program is particularly relevant for:

Nephrologists • Oncologists • Hematologists • Internal Medicine Physicians • Hospitalists • Fellows • Residents • Advanced Practice Providers • Nurses • Medical Students • Other healthcare professionals involved in cancer and kidney care

The official course specifically identifies healthcare professionals in nephrology, oncology, hematology, internal medicine and hospital medicine among its intended audience.